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Abstract
Background: The lymphatic system is a major route for cancer cell dissemination and also a potential target for
antitumor therapy. To investigate whether increased lymphatic vessel density (LVD) is a prognostic factor for nodal
metastasis and survival, we studied peritumoral LVD (P-LVD) and intratumoral LVD (I-LVD) in samples from 102
patients with endometrial carcinoma;
Methods: Endometrial carcinoma tissues were analyzed for lymphatic vessels by immunohistochemical staining
with an antibody against LYVE-1. Univariate analysis was performed with Kaplan-Meier life-table curves to estimate
survival, and was compared using the log rank test. Prognostic models used multivariate Cox regression analysis for
multivariate analyses of survival;
Results: Our study showed that P-LVD, but not I-LVD, was significantly correlated with lymph vascular space
invasion (LVSI), lymph node metastasis, tumor stage, and CD44 expression in endometrial carcinoma. Moreover, P-
LVD was an independent prognostic factor for progression-free survival and overall survival of endometrial
carcinoma;
Conclusions: P-LVD may serve as a prognostic factor for endometrial carcinoma. The peritumoral lymphatics might
play an important role in lymphatic vessel metastasis.
Background
Endometrial cancer is the most frequent gynaecologic
genital malignancy in the western world [1,2] and the
five-year overall survival rate for patients with advanced
stage cancer is about 65% [3]. Traditional prognostic
factors for the disease are histological type, grade, tumor
stage, and depth of myometrial invasion. However, even
for the patients in the same stage the clinical courses
are highly variable. The current diagnostic technology is
insufficient to identify endometrial cancer patients with
poor prognosis. Since dissemination through lymphatic
vessels is the main means of tumor spread, we hypothe-
sized that lymphatic vessel density (LVD) might serve as
a prognostic marker for lymph node metastasis and
survival.
Lymphangiogenesis has been difficult to study because
of the lack of specific lymphatic markers. Recently, this
situation has changed with the discovery of lymphangio-
genic markers, such as VEGF-C, VEGF-D, VEGFR-3,
LYVE-1, PROX1, and podoplanin. Among them, LYVE-
1 is a reliable specific marker for lymphatics [4,5]. It is a
surface endocytic receptor for hyaluronan [6], which
shares 41% homology with the metastasis related CD44
molecule [7]. CD44 binds to hyaluronic acid (HA),
major components of the extracellular matix (ECM) and
CD44 is important in tumor progression and metastasis
[8]. In common with CD44, the LYVE-1 molecule binds
both soluble and immobilized HA. HA continuously
transits through the lymphatic system and is potentially
involved in lymph node homing by CD44+ leukocytes
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and tumor cells [9]. However, little is known about the
role of LYVE-1 in lymphatic metastasis.
In this study, LYVE-1 staining was used to determine
LVD in tissue samples from endometrial carcinoma
patients. The findings were analyzed in combination
with data regarding lymph node metastasis, lymph vas-
cular space invasion (LVSI), CD44 expression, and other
clinicopathological parameters. The potential of intratu-
moral LVD (I-LVD) and peritumoral LVD (P-LVD) as
prognostic factors for lymph node metastasis, progres-
sion-free survival and overall survival was investigated.
Methods
Materials
One hundred and two endometrial hysterectomy speci-
mens containing endometrial carcinoma tissue were
obtained from the pathological archives of the 1st
Affiliated Hospital of Medical College of Xi’an Jiaotong
University from January 1997 to July 2002. Patients with
a disease other than endometrial carcinoma were
excluded. The present study was approved by the ethics
committee of the 1st Affiliated Hospital of Medical Col-
lege of Xi’an Jiaotong University. All samples were
obtained with medical-ethics approval and all patients
gave informed consent. All haematoxylin and eosin-
stained slides were re-reviewed by a gynaecological
pathologist to confirm the diagnosis, histological grade,
histological type, surgical stage and lymphangiosis. Patho-
logical stage and histological type were determined
according to 1988 International Federation of Gynecology
and Obstetrics (FIGO) criteria. Histological classification
was performed according to the World Health Organiza-
tion (WHO) system in well-differentiated (G1; n = 39),
moderately differentiated (G2; n = 32) and poorly
differentiated (G3; n = 31) carcinomas. Patients with
endometrial carcinoma received radical hysterectomy, sal-
pingo-oophorectomy, or selective pelvic lymphadenect-
omy, with or without para-aortic lymphadenectomy.
Lymph node dissection was generally performed in
patients having tumors with deep myometrial invasion
and/or high-grade or aggressive histological features. The
standard for lymphatic vessel invasion was the micro-
scopic detection of cancer cells in the cavity of the lym-
phatic vessel by light microscopy.
All cases of recurrence had radiologic evidence or
biopsy-proven progression of disease. Only the records
of patients who died of disease were considered to be
uncensored; the records of all patients who were alive at
follow-up or who did not die of disease (or a related
cause) were considered to be censored. Another 16
patients with non-tumor endometrial diseases under-
going routine endometrial biopsy were included as nor-
mal controls (NE).
Methods
The antibody against LYVE-1 was purchased from R&D
Systems (USA). Sections were dewaxed and antigen
retrieval was carried out by microwaving in retrieval
buffer (pH 6.0), three times for four minutes each. Slides
were incubated in phosphate buffered saline (PBS) with
5% human serum for 5 minutes. Peroxidase was
quenched with methanol and 3% H2O2 for 15 minutes.
Then slides were incubated in antibodies to LYVE-1
(monoclonal mouse anti-human antibody 1.25 lg/ml),
CD44 (DAKO, Denmark; mouse monoclonal antibody,
1:40). After incubation with the primary antibodies in
PBS plus 5% fetal calf serum for 45 minutes and wash-
ing with PBS, sections were incubated with a secondary
anti-mouse horseradish peroxidase conjugated antibody
for 15 minutes and washed in PBS. The color was devel-
oped during a 15-minute incubation with diaminobenzi-
dine (DAB) solution (DAKO) and sections were weakly
counterstained with haematoxylin. Normal tissue sec-
tions from the small intestine were used as positive con-
trols. PBS was substituted for primary antibody as the
negative control.
Determination of CD44 levels
Only nuclear staining of cells was considered positive
for CD44. The neoplastic cells that were positively
stained for CD44 antigen were counted in 10 high
power fields (magnification factor of 400) for each tissue
section and were scored semi-quantitatively as <10%,
between 10% and 70%, or >70% cells positive [10].
Lymphatic vessel counting
Lymphatic vessel counting was performed in the intratu-
moral, peritumoral, and normal tissues. As described by
Ohno and Weidner [11,12], the areas of highest vascu-
larization were chosen at low power (×100) and vessels
were counted in three high power (×200) fields. The
lymphatic vessel density (LVD) was the mean of the ves-
sel counts obtained in these three fields.
Data analysis
Data are given as mean ± SD. A one-way ANOVA test
was used to evaluate the association between I-LVD or
P-LVD and clinicopathological parameters. Survival
curves were plotted using the method of Kaplan-Meier
and compared using the log-rank test by dividing the
two groups by their LVD at the mean value to give two
similar-sized groups. A multivariate model using Cox
stepwise regression analysis was used to assess the effect
of tumor variables on survival. Differences were consid-
ered statistically significant for P values less than 0.05.
Statistical analysis was done using SPSS statistical soft-
ware (SPSS version 16.0).
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Results
Clinicopathological characterization
The median age of the 102 patients at the time of diag-
nosis was 52.9 years (range 42-62 years). Forty-seven
(46.1%) patients were diagnosed in FIGO stage I and
twenty-six (25.5%) patients were diagnosed in FIGO
stage II, whereas 29 (28.4%) were diagnosed in FIGO
stage III. Seventy-six patients had an endometrioid ade-
nocarcinoma (74.5%), 6 (6%) had adenoacanthoma carci-
noma, 17 (16.6%) had papillary serous, and 3 (2.9%) had
clear cell carcinoma. Lymph node sampling or dissection
was generally performed in patients with deep myome-
trial invasion and/or high-grade or aggressive histologi-
cal features. Pelvic and/or para-aortic lymph node
sampling was performed for 59 patients (57.8%) and 27
of these (26.5%) had lymph node metastasis. Patient
characteristics are outlined in Table 1. Of the 102
patients analyzed, 38 patients (37.3%) received radiation
therapy and 18 (17.6%) denied a recommended radiation
therapy. Thirty-five patients (34.3%) received an anti-
hormone treatment. During the follow-up interval, 27 of
102 (26.5%) patients died. Tumor recurrence and metas-
tasis were observed in 26 patients (25.5%) and 21
patients (20.6%) died of the tumor-related disease. The
other 6 patients died of causes other than endometrial
cancer.
LYVE-1+ lymphatics in endometrial carcinoma
Lymphatic vessels were observed in EC (endometrial
carcinoma) and NE (normal endometrium) specimens
(Fig. 1a). LYVE-1+ cells were predominantly found in
the peripheral regions of tumor nests; staining was weak
in intratumoral regions. LYVE1 staining in peripheral
regions was interpreted as positive in 94 of the 102
(92.2%) samples. Within tumors, 64 (62.7%) of the 102
samples were positive. Inside the tumors, the small ves-
sels with LYVE-1+ endothelial cells were of irregular
shape without a thick-walled structure (Fig. 1c). In con-
trast, prominently large, irregular morphology, thin-
walled lymphatics were detected at the periphery of the
Table 1 Relationship Between P-LVD or I-LVD and Clinical or Pathological variables in endometrial carcinoma
N P-LVD P-value I-LVD P-value
Histologic subtype
Endometrioid 76 20.62 ± 4.04 4.43 ± 1.11
Adenoacanthoma 6 18.28 ± 4.40 0.540 4.08 ± 1.85 0.767
Papillary serous 17 19.71 ± 4.79 4.07 ± 1.27
Clear cell 3 19.67 ± 7.54 4.00 ± 0.47
Stage
I 47 20.30 ± 3.92 0.016 4.25 ± 1.28 0.361
II 26 18.49 ± 4.93 4.15 ± 1.27
III 29 21.79 ± 3.51 4.60 ± 0.83
Grade
Well differentiated 39 20.90 ± 4.57 0.576 4.59 ± 1.09 0.282
Moderately differentiated 32 19.89 ± 4.29 4.04 ± 1.34
Poorly differentiated 31 20.00 ± 3.78 4.42 ± 0.96
Myometrial invasion
≥1/2 56 19.91 ± 4.67 0.543 4.45 ± 1.03 0.415
>1/2 46 20.60 ± 4.08 4.21 ± 1.31
Nodal status
Positive 27 22.08 ± 3.60 0.011 4.76 ± 0.87 0.074
Negative 75 19.62 ± 4.28 4.19 ± 1.23
CD44 expression
<10% 13 16.93 ± 1.84 0.000 3.84 ± 2.19 0.049
10%-70% 55 18.89 ± 3.53 4.14 ± 1.06
>70% 44 23.18 ± 3.96 4.84 ± 0.97
LVSI
Positive 15 25.82 ± 2.79 0.000 4.86 ± 1.22 0.219
Negative 97 19.41 ± 3.73 4.29 ± 1.14
Age
≤55 54 20.00 ± 4.04 0.543 4.42 ± 1.06 0.682
>55 58 20.54 ± 4.40 4.30 ± 1.23
P-LVD, peritumoral lymphatic vessel density; I-LVD, intratumoral lymphatic vessel density.
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tumor. Some small and depressed vessels were detected
inside the carcinoma tissue (Fig. 1b and 1c). In the 94
LYVE1+ samples, the mean density at the tumor periph-
ery (P-LVD) was 20.30 ± 4.23 vessels/mm2. In intratu-
moral regions, the average density (I-LVD) was
significantly lower: 4.35 ± 1.15 vessels/mm2. Both densi-
ties were significantly different from the density in nor-
mal control tissue (17.17 ± 2.13 vessels/mm2).
Association of LVD with clinicopathological parameters
P-LVD was significantly correlated with lymph node
metastasis, LVSI, tumor stage and CD44 expression in
endometrial carcinoma (Table 1, P < 0.05). In cases with
nodal metastasis, P-LVD was 22.08 ± 3.60 vessels/mm2
(P = 0.011, compared with P-LVD in negative nodal
metastasis cases 19.62 ± 4.28 vessels/mm2). In addition,
P-LVD was significantly associated lymphatic vessel
invasion (P < 0.01). In 102 endometrial carcinoma cases,
CD44 was immunohistochemically detected in 94 cases
(92.2%). P-LVD in patients with strong nuclear CD44
staining of cells (>70%) was 23.18. ± 3.96 vessels/mm2,
P-LVD in samples with intermediate CD44 expression
(10-70%) was 18.89. ± 3.53 vessels/mm2, and in those
with weak CD44 expression (10%) P-LVD was 16.93. ±
1.84 vessels/mm2 (P < 0.01). The staining of CD44 was
stronger in endometrial carcinoma tissue with LYVE1+
lymphatic vessels than without LYVE1+ lymphatic ves-
sels (Fig. 1e and 1f). In multivariate analysis, P-LVD was
independently correlated with LVSI, tumor stage and
CD44 expression (P = 0.561).
No significant difference in I-LVD was observed in
samples from patients with and without nodal
metastasis (P = 0.074). I-LVD was similar between the
patients with LVSI and those without LVSI (P = 0.219).
I-LVD was significantly correlated with CD44 staining,
however (Table 1, P = 0.049). The differences in I-LVD
between different tumor stages had no statistical signifi-
cance. The tumors associated with increased P-LVD or
I-LVD tended to have higher CD44 expression, higher
tumor stage, and nodal metastasis. No significant asso-
ciation was found between P-LVD or I-LVD and the
depth of myometrial invasion, histological classification,
or grade. There was no correlation between LVD and
patient age (Table 1).
Survival analysis
The mean follow-up time was 54.2 months (range 5-79
months). During the follow-up interval, 27 of 102
(26.5%) patients died of disease. Twenty patients devel-
oped pelvic local recurrence (among them, 15 patients
were presented strong CD44 staining). Six patients had
distant dissemination (including three cases of relapse in
the lung, one case of liver metastasis, one case multiple
metastasis, and one case of para-aortic nodal metastasis).
The 5-year survival rate was 73.5% and progression-free
survival rate was 68.6%. To analyze the correlation
between I-LVD or P-LVD and survival, patients were
divided into two groups: one group with P-LVD or I-
LVD higher than mean and another group with P-LVD
or I-LVD lower than the mean. In univariate analysis,
increased P-LVD was associated with poorer overall sur-
vival (P < 0.01, Fig. 2a) and less likelihood of progres-
sion-free survival (P < 0.01, Fig. 2b). A significantly
better survival rate and likelihood of progression-free
Figure 1 a LYVE-1, normal endometrial tissue (NE), 200×. b LYVE-1, periphery regions in endometrial carcinoma (EC) tissue, 200×. c LYVE-1,
intratumoral regions in endometrial carcinoma (EC) tissue, 200×. LYVE-1 expression was restricted to irregular shaped endothelial cells without a
thick-walled structure. Number of lymphatic vessels was much higher in periphery tumour than intratumoral regions (b and c). d The staining of
CD44, normal endometrial tissue (NE), 200×. e CD44, in endometrial carcinoma (EC) tissue without LYVE1+ lymphatic vessels, 200×. f CD44, in
endometrial carcinoma (EC) tissue with LYVE1+lymphatic vessels, 200×. The staining of CD44 was stronger in endometrial carcinoma (EC) tissue
with LYVE1+lymphatic vessels than without LYVE1+ lymphatic vessels (e and f).
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survival was found in patients with lower P-LVD. In
contrast, the presence of I-LVD was not associated with
survival (P > 0.05, Fig. 2c and Fig. 2d). Other clinical
parameters, including LVSI, FIGO stage, histologic sub-
type, and nodal status of endometrial cancer, signifi-
cantly affected the survival rates in the evaluated
patients, demonstrating the validity of the patient group
enrolled in our study (P in log rank was <0.01 for both
progression-free and overall survival). Cox regression
analysis allowed us to construct a prognostic model con-
taining three independent terms that were predictive of
overall and progression-free survival: P-LVD, FIGO
stage, and histologic subtype (P < 0.05). Nodal involve-
ment and LVSI were not independent prognostic factors
in a multivariate survival analysis (Table 2).
Discussion
The study of lymphatics has been facilitated by the iden-
tification of the lymphatic marker LYVE-1 [13-17].
LYVE-1 is found in lymphatic endothelium and not in
blood vascular endothelium except in the sinusoidal
endothelium of liver and spleen where uptake and
degradation of HA is known to occur [17]. There is
controversy regarding lymphatics and lymphangiogenesis
in the endometrium. There is a report that lymphatic
vessels of endometrial adenocarcinomas were located
both intra- and peri-tumorally and that vessel density
was significantly higher than in normal basalis; more-
over, a potential vascular-control feedback loop was
indentified [18]. In contrast, two studies reported an
absence of human endometrial lymphatics [19,20]. In
this study, LYVE-1 positive vessels were identified as
lymphatics in endometrial carcinoma tissue. The I-LVD
Figure 2 Survival analysis of increased P-LVD and I-LVD in endometrial carcinoma. a Overall-survival curve stratified for increased versus
decreased P-LVD (P < 0.01). b Progression-free survival curve stratified for increased versus decreased P-LVD (P < 0.01). c Overall-survival curve
stratified for increased versus decreased I-LVD (P > 0.05). d Progression-free survival curve stratified for increased versus decreased I-LVD (P >
0.05).
Table 2 Cox regression analysis determining the
independent effect of prognostic variables on survival
varible progression-free survival overall survival
HR 95%CI p-value HR 95%CI p-value
Histologic subtype 1.5 1.1-2.0 0.005 1.6 1.2-2.1 0.003
Stage 2.4 1.3-4.4 0.005 2.3 1.2-4.4 0.014
Nodal metastasis 1.8 0.6-5.4 0.309 1.5 0.5-5.0 0.487
P-LVD 0.2 0.1-0.6 0.003 0.3 0.1-0.8 0.019
LVSI 1.1 0.4-2.8 0.872 1.4 0.5-3.7 0.479
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of carcinoma tissue was significantly lower than that of
normal tissue, whereas the P-LVD was higher. In our
experiment, small, depressed lymph vessels were mostly
observed within the carcinoma tissues and the peritu-
moral lymph vessels were large and dilated. Lymphatic
vessels formed anastomoses and possessed frequent
blind endings that were occasionally open. Tripp et al.
[21] found inter-connected LYVE-1+ vessels that went
into the deeper dermis in skin. Similarly, a lymphatic
network may exist in endometrial tumors in both the
peripheral and intratumoral regions. This data contra-
dicts a study by Kouk et al. [20] that did not find intra-
tumoral lymph vessels or an intratumoral lymphatic
network in endometrial carcinomas. It seems clear that
lymphatic and vascular systems have numerous connec-
tions that allow disseminating cancer cells to pass
rapidly from one system to another [22]. The formation
of a lymphatic network within a tumor greatly facilitates
tumor growth by draining waste products of metabolism
and promoting lymphatic dissemination of tumor cells.
As a tumor grows, the lymphatics inside the tumor are
compressed or destroyed and become difficult to detect
by immunohistochemistry. This is consistent with our
findings that the I-LVD of carcinoma tissues was signifi-
cantly lower and the P-LVD was significantly higher
than that of normal endometrium. Two recent studies
in melanoma (using the anti-LYVE-1) confirmed the
presence of focal areas exhibiting intratumoral lymphatic
proliferation [23,24]. In addition, the presence of intra-
tumoral lymphatics in laryngeal carcinoma may assist
tumor spread to regional lymph nodes [25]. However,
whether intratumoral lymphangiogenesis is necessary for
or enhances lymphatic metastasis is still unclear.
In our study, the P-LVD had the highest correlation
with patient survival of the parameter evaluated. The
peritumoral lymphatics are likely important for dissemi-
nation of endometrial carcinoma cells. In support of this
hypothesis, our study demonstrated that high P-LVDs
were associated with LVSI, lymph nodes metastasis, and
poor likelihood of survival. The results showed that
LYVE1 is a useful prognostic tool. The lymphangiogen-
esis and location of lymphatic vessels relative to a pri-
mary tumor may be a determinant of metastatic spread.
As reviewed by Achen [26], the VEGF-C/VEGF-D/
VEGFR-3 axis was the best validated signaling system
implicated in promoting lymphangiogenesis in solid
tumors and the metastatic spread of tumor cells to
lymph nodes. These growth factors were also likely can-
didates for driving lymph node lymphangiogenesis and
appear to promote metastatic spread to sentinel lymph
nodes and perhaps to more distant sites. Metastasis may
also depend on the position of the primary tumor rela-
tive to the lymphatic network. P-LVD may be a determi-
nant of metastatic spread as studies in animal models
indicate that peritumoral lymphatics are capable of
draining fluid and cells from a tumor whereas intratu-
moral lymphatics are nonfunctional [27]. It may be that
an extensive peritumoral lymphatic network produces
high concentrations of VEGF-C and other growth fac-
tors that promote angiogenesis and lymphangiogenesis
of distant metastases, enhancing further dissemination
and growth of cancer. The peritumoral lymphatics may
be a target for inhibition of metastasis. Clinically, the
patients with high P-LVD should be considered for early
chemotherapy and should be re-evaluated often.
In addition to lymphangiogenesis, the interaction
between epithelial tumor cells and their surrounding
stroma is important in tumor progression and metasta-
sis. As a transmembrane receptor interacting with stro-
mal ECM, CD44 plays an important role in the process
through binding to HA. It was reported that with hyper-
plasia, increasing atypia and adenocarcinoma [8], the
levels of stromal HA, glandular CD44v6, and glandular
and stromal CD44s increase. CD44 facilitates breast can-
cer progression through alterations of tumor cell adhe-
sion characteristics [28,29]. CD44 is a mesenchymal
stem cell (MSC) marker; the rare epithelial progenitors
and MSCs are likely responsible for regenerative capa-
city that plays a critical role in the development of
endometriosis and endometrial cancer. Several versions
of CD44v6-specific antibodies have been tested in clini-
cal trials and preliminary results are promising [30]. It
may provide a readily available source of MSCs for cell-
based therapies [31]. The CD44 gene contains at least
20 exons, 10 of which can be alternatively spliced to
form a variety of isoforms. Exons 6-15 can be alterna-
tively spliced to generate many CD44 variants (CD44v)
mainly expressed on epithelial cells [32]. CD44v8-10 is
overexpressed in various malignant tumors and is con-
sidered to be associated with the presence of tumor or
with tumor progression. An elevated CD44v8-10-to-
standard CD44 ratio in urinary samples may serve as a
novel prognostic predictor in patients with urothelial
cancer [33]. CD44v8-v10 can be produced from epithe-
lial cells, but no studies have addressed CD44v8-v10
expression on lymphatics until now. Here we found that
CD44 had prognostic significance. Both increased P-
LVD and I-LVD were correlated with stronger CD44
staining. Although patients with high levels of CD44
staining did not have significantly reduced overall or
progression-free survival in our study, 15 of the 20
patients who developed pelvic local recurrence had
strong CD44 staining. Alterations of CD44 expression
occurred during local pelvic recurrence. In contrast, the
alterations of LYVE1 were associated with the dissemi-
nation of the disease. The main physiological functions
of LYVE-1 include serving as a receptor for HA and
facilitating the transport and metabolism of HA in the
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extracellular matrix. It has also been shown that LYVE-1
is involved in adherence of tumor cells [9]. LYVE-1 may
promote tumor lymph node metastasis and lymphatic
invasion. Based on their similar adhesive functions,
LYVE1 and CD44 may both contribute to metastatic
spread of cancer cells since HA is more abundant in the
surrounding stroma than in the tumor itself. From a
clinical point of view, the analysis of LYVE1 and CD44
expression in endometrial carcinomas may help to iden-
tify patients with poor prognosis who may benefit from
adjuvant therapies.
Conclusions
P-LVD was significantly correlated with lymph node
metastases, lymph vascular space invasion (LVSI), tumor
stage, and CD44 expression in endometrial carcinoma
samples. The P-LVD was an independent risk factor for
progression-free survival and overall survival. Therefore,
P-LVD may serve as a prognostic factor in endometrial
carcinoma and the peritumoral lymphatics might play
an important role in lymphatic vessel metastasis.
Acknowledgements
This research is supported by a grant of the 1st Affiliated Hospital of Medical
College of Xi’an Jiaotong University and Dr. Gang Zheng.
Authors’ contributions
YG was the guarantor of integrity of the entire study and designed the
experiment, carried out the immunohistochemical method studies and
drafted the manuscript. ZL participated in literature research, data analysis
and manuscript editing. FG participated in the design of the study and
performed the statistical analysis. X.Y-M carried out the
immunohistochemical method studies and participated in manuscript
preparation. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 4 July 2009 Accepted: 8 April 2010 Published: 8 April 2010
References
1. Sherman ME: Theories of endometrial carcinogenesis: a multidisciplinary
approach. Mod Pathol 2000, 13:295-308.
2. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I:
Endometrial cancer. Lancet 2005, 366:491-505.
3. Kyo S, Hashimoto M, Maida Y, Mizumoto Y, Nakamura M, Takakura M,
Inoue M: Analysis of outcome of Stage I-III endometrial cancer treated
with systematic operation omitting paraaortic lymphadenectomy. Eur J
Gynaecol Oncol 2007, 28:170-173.
4. Kato T, Prevo R, Steers G, Roberts H, Leek RD, Kimura T, Kameoka S,
Nishikawa T, Kobayashi M, Jackson DG, Harris AL, Gatter KC, et al: A
quantitative analysis of lymphatic vessels in human breast cancer, based
on LYVE-1 immunoreactivity. Br J Cancer 2005, 93:1168-1174.
5. Gao P, Zhou GY, Zhang QH, Xiang L, Zhang ShL, Li C, Sun YL:
Clinicopathological significance of peritumoral lymphatic vessel density
in gastric carcinoma. Cancer Lett 2008, 263:223-230.
6. Prevo R, Banerji S, Ferguson DJ, Clasper S, Jackson DG: Mouse LYVE-1 is an
endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem
2001, 276:19420-19430.
7. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG:
LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific
receptor for hyaluronan. J Cell Biol 1999, 144:789-801.
8. Afifty AM, Craiq S, Paulino AF, Stern R: Expression of hyaluronic acid and
its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic
endometrium. Ann Diagn Pathol 2005, 9:312-318.
9. Jackson DG, Prevo R, Clasper S, Banerji S: LYVE-1, the lymphatic system
and tumor lymphangiogenesis. Trends Immunol 2001, 6:317-321.
10. Saddik M, Lai R: CD44s a surrogate marker for distinguishing intraductal
papilloma from papillary carcinoma of the breast. J Clin Pathol 1999,
52:862-864.
11. Ohno M, Nakamura T, Kunimoto Y, Nishimura K, Chung-Kang C, Kuroda Y:
Lymphagenesis correlates with expression of vascular endothelial
growth factor Cincolorectal cancer. Oncol Rep 2003, 10:939-943.
12. Weidner N: Tumor angiogenesis: review of current applications in tumor
prognostication. Semin Diagn Pathol 1993, 10:302-313.
13. Witte MH, Jones K, Wilting J, Dictor M, Selq M, Mchale N, Gershenwald JE,
Jackson DG: Structure function relationships in the lymphatic system and
implications for cancer biology. Cancer Metastasis Rev 2006, 25:159-184.
14. Schaft Vander DW, Pauwels P, Hulsmans S, Zimmermann M, Poll-Franse Van
de LV: Absence of lymphangiogenesis in ductal breast cancer at the
primary tumor site. Cancer Lett 2007, 254:128-136.
15. Shields JD, Borsetti M, Rigby H, Harper SJ, Mortimer PS, Levick JR,
Orlando A, Bates DO: Lymphatic density and metastatic spread in human
malignant melanoma. Br J Cancer 2004, 90:693-700.
16. Gao F, Lu YM, Cao ML, Liu YW, He YQ, Wang Y: Expression and
quantification of LYVE-1 in human colorectal cancer. Clin Exp Med 2006,
6:65-71.
17. Omachi T, Kawai Y, Mizuno R, Nomiyama T, Miyaqawa S, Ohhashi T,
Nakayama J: Immunohistochemical demonstration of proliferating
lymphatic vessels in colorectal carcinoma and its clinicopathological
significance. Cancer Lett 2007, 246:167-172.
18. Donoghue JF, Lederman FL, Susil BJ, Rogers PA: Lymphangiogenesis of
normal endometrium and endometrial adenocarcinoma. Hum Reprod
2007, 22:1705-1713.
19. Red-Horse K, Rivera J, Schanz A, Zhou Y, Winn V, Kapidzic M, Maltepe E,
Okazaki K, Kochman R, Vo KC, Giudice L, Erlebacher A, et al:
Cytotrophoblast induction of arterial apoptosis and lymphangiogenesis
in an in vivo model of human placentation. J Clin Invest 2006,
116:2643-2652.
20. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Gatter KC,
Harris AL, Jackson DG: LYVE-1 immunohistochemical assessment of
lymphangiogenesis in endometrial and lung cancer. J Clin Pathol 2005,
58:202-206.
21. Tripp CH, Haid B, Flacher V, Sixt M, Peter H, Farkas J, Gschwentner R,
Sorokin L, Romani N, Stoitzner P: The lymph vessel network in mouse skin
visualised with antibodies against the hyaluronan receptor LYVE1.
Immunobiology 2008, 213:715-728.
22. Carr I, Orr FW: Invasion and metastasis. Can Med Assoc J 1983,
128(10):1164-1167.
23. Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG,
Ellwanger U, Garbe C, Mihm MC, Detmar M: Tumor lymphangiogenesis: a
novel prognostic indicator for cutaneous melanoma metastasis and
survival. Am J Pathol 2003, 162:1951-1960.
24. Straume O, Jackson DG, Akslen LA: Independent prognostic impact of
lymphatic vessel density and presence of low-grade lymphangiogenesis
in cutaneous melanoma. Clin Cancer Res 2003, 9:250-256.
25. Audet N, Bersley NJ, Mac Milllan C, Jackson DG, Gullane Pj, Kamel-Reid S:
Lymphatic Vessel Density, Nodal Metastases, and Prognosis in Patients
With Head and Neck Cancer. Arch Otolaryngol Head Neck Surg 2005,
131:1065-1070.
26. Achen MG, Stacker SA: Molecular Control of Lymphatic Metastasis. Ann N
Y Acad Sci 2008, 1131:225-34.
27. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y,
Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK: Lymphatic
metastasis in the absence of functional intratumor lymphatics. Science
2002, 296:1883-1886.
28. Draffin JE, McFarlane S, Hill A, Johnston PG, Waugh DJ: CD44 potentiates
the adherence of metastatic prostate and breast cancer cells to bone
marrow endothelial cells. Cancer Res 2004, 64:5702-5711.
29. Paltian V, Alldinger S, Baumgärtner W, Wohlsein P: Expression of CD44 in
Canine Mammary Tumours. J Comp Path 2009, 1-11.
30. Heider KH, Kuthan H, Stehle G, Munzert G: CD44v6: a target for antibody-
based cancer therapy. Cancer Immunol Immunother 2004, 53:567-579.
Gao et al. BMC Cancer 2010, 10:131
http://www.biomedcentral.com/1471-2407/10/131
Page 7 of 8
31. Gargett CE, Schwab KE, Zillwood RM, Nguyen HP, Wu D: Isolation and
culture of epithelial progenitors and mesenchymal stem cells from
human endometrium. Biol Reprod 2009, 80:1136-1145.
32. Goodison S, Tarin D: Clinical implications of anomalous CD44 gene
expression in neoplasia, Front. Biosci 1998, 3:e89-e109.
33. Miyake H, Eto H, Arakawa S, Kamidono S, Hara I: Over expression of
CD44V8-10 in urinary exfoliated cells as an independent prognostic
predictor in patients with urothelial cancer. J Urol 2002, 167:1282-1287.
Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.
biomedcentral.com/1471-2407/10/131/prepub
doi:10.1186/1471-2407-10-131
Cite this article as: Gao et al.: High density of peritumoral lymphatic
vessels is a potential prognostic marker of endometrial carcinoma: a
clinical immunohistochemical method study. BMC Cancer 2010 10:131.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gao et al. BMC Cancer 2010, 10:131
http://www.biomedcentral.com/1471-2407/10/131
Page 8 of 8
